Atlantic Power & Infrastructure (AP&I) Emerges as Top Choice for Educational Institutions With Its Flexi(R)-Pave Installations
Atlantic Power & Infrastructure Corp. (OTC PINK:AWSL) continues to gain momentum with the increasing adoption of its Flexi®-Pave technology by educational institutions across the country. CLEARWATER, FL & TAMPA BAY, FL / ACCESSWIRE / September 11, 2024 / Atlantic Power & Infrastructure Corp. (OTC PINK:AWSL) continues to gain momentum with the increasing adoption of its Flexi®-Pave technology by educational institutions across the country.
Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Ryder System, Inc. (R) Settlement Fund Before Deadline
NEW YORK, NY / ACCESSWIRE / September 3, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE:R). The settlement provides for a fund of $45,000,000 to benefit class members.
Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Ryder System, Inc. (R) Settlement Fund Before Deadline
NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE:R). The settlement provides for a fund of $45,000,000 to benefit class members.
Ryder System, Inc. (R) Shareholders - L&K, LLP Encourages you to File a Claim Against the Settlement Fund Before Deadline
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE:R). The settlement provides for a fund of $45,000,000 to benefit class members.
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules
Absorption improvements appear to continue with DehydraTECH-processed Rybelsus® vs. Rybelsus® tablets even under "fed" conditions DehydraTECH-treated Rybelsus® does absorb through a mouth-melt product format KELOWNA, BC / ACCESSWIRE / August 29, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that tolerability and additional pharmacokinetic ("PK") results from human pilot study #2, GLP-1-H24-2, (the "Study") have been received.
Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product
Assisi's tPEMF™ technology aligns with Fear Free's mission to “prevent and alleviate fear, anxiety, and stress in pets” ANN ARBOR, MI / ACCESSWIRE / August 29, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering therapeutic and diagnostic products for equine and companion animals, is pleased to announce that its Assisi Loop® product line is continuing its designation as a Fear Free Preferred Product. Fear Free, a globally recognized initiative dedicated to reducing fear, anxiety, and stress in pets, reaffirmed its validation of Assisi's targeted pulsed electromagnetic field (tPEMF) technology, which is designed to reduce inflammation and pain, accelerate healing, and alleviate canine separation anxiety.
Rutherrin(R) Increases Efficacy of Chemotherapy for Lung Cancer
TORONTO, ON / ACCESSWIRE / August 28, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation and or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation, Rutherrin®, has demonstrated an ability to provide a significant enhancement of Cisplatin efficacy in chemotherapy resistant Non-Small Cell Lung Cancer ("NSCLC") in a preclinical animal model. Theralase® recently press released its latest research, using the well-established Lewis Lung Cancer ("LLC1") orthotopic model, representing NSCLC.
R Stock Hits 52-Week High on Dividend Strength: More Upside Ahead?
The Ryder stock appreciates more than 25% in the past six months on multiple tailwinds.
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn(R) Disinfectant & Sanitizer has been Approved by the Australian TGA as Effective Against Candida auris and C-Diff
BOULDER, CO / ACCESSWIRE / August 26, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, and its partner, the MicroSafe Group DMCC, announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma's patented Microcyn® technology. Nanocyn® was previously approved by the TGA and entered into The Australian Register of Therapeutic Goods with a 15 second kill time against SARS-CoV-2 (COVID 19), and a 30 second kill time against Norovirus (Gastro), Influenza A (H1N1), and bacteria, such as Staphylococcus aureus (MRSA), E.
Here's Why Investors Should Retain Ryder (R) Stock for Now
Ryder (R) rides high on its robust cost-cutting initiatives and solid segmental performance. However, sluggish freight market conditions are a major headwind.
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
CAMBRIDGE, MA / ACCESSWIRE / August 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The marketing authorization follows the Positive Opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
Time Sensitive - Reminder from Levi & Korsinsky, LLP to File Claim for Share of Ryder System, Inc. (R) Settlement Fund Before Deadline
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE:R). The settlement provides for a fund of $45,000,000 to benefit class members.
